Yung Shin Pharm. Ind. Co., Ltd.   Report issue

For profit Phase 2 Phase 4
Founded: Taichung Taiwan (1952)
Status: No NME R&D (1952)

Organization Overview

First Clinical Trial
2011
NCT02152800
First Marketed Drug
2004
cefaclor (ceclor)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

YUNG SHIN PHARM | Yung Shin Pharmaceutical Ind. Co., Ltd. | Yung Shin Pharm. Ind. Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Duodenal Ulcer (Phase 4)

Epilepsies, Partial (Phase 4)

Epilepsy (Phase 4)

Fibromyalgia (Phase 4)

Hepatitis B (Phase 4)

Herpes Labialis (Phase 2)

Herpes Simplex (Phase 2)

Herpes Zoster (Phase 4)

Hot Flashes (Phase 2)

Mycoses (Phase 4)

Pain, Postoperative (Phase 4)

Peripheral Nervous System Diseases (Phase 4)

Seizures (Phase 4)

Ulcer (Phase 4)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 20